A. Bardelli

Molecular Biology · 2001–2017

A researcher in the Science corpus: 24 papers; trusts 4 researchers and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

Whom A. Bardelli trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. L. Diaz

Who trusts A. Bardelli overall

  1. A. Young
  2. Yardena Samuels

Papers from A. Bardelli's perspective

Ordered by how strongly the researchers A. Bardelli trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood (Proceedings of the National Academy of Sciences of the United States of America)
  2. Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer (Nature)
  3. Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion (Nature)
  4. The PIK3CA gene is mutated with high frequency in human breast cancers (Cancer Biology & Therapy)
  5. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors (Nature)
  6. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. (Journal of Clinical Oncology)
  7. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. (Annals of Oncology)
  8. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (PLoS Medicine)
  9. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. (Journal of Clinical Oncology)
  10. PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)

Their papers